Investigational drug · Phase 3
Nizubaglustat
Also called: AZ-3102
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Niemann-Pick Type C Disease, GM2 Gangliosidosis, GM1 Gangliosidosis.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
6
Any phase or sponsor naming "Nizubaglustat"
First trial start
2025
Jun 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Nizubaglustat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Niemann-Pick Type C Disease
- GM2 Gangliosidosis
- GM1 Gangliosidosis
- Gaucher Disease Type 3
- Niemann-Pick Disease Type C
- Gangliosidoses, GM2
- Gangliosidosis, GM1
Approved drugs for the same conditions: Gaucher disease · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Nizubaglustat" as an intervention, largest first.
- Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal DisordersPivotal-lookingNot yet recruiting
Azafaros B.V.Industry
NCT07885917 · 218 participants (planned) · Start Dec 10, 2026 · Primary completion Apr 1, 2030
Drug: AZ-3102 · For: Niemann-Pick Disease Type C; GM2 Gangliosidosis; GM1 Gangliosidosis and 1 more
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 GangliosidosisPivotal-lookingRecruiting
Azafaros B.V.Industry
NCT07054515 · 147 participants (planned) · Start Jun 30, 2025 · Primary completion May 14, 2028
Drug: AZ-3102; Placebo · For: Niemann-Pick Type C Disease; GM1 Gangliosidosis; GM2 Gangliosidosis
Sites: Oakland, California; Minneapolis, Minnesota; Rochester, Minnesota · 39 sites in all
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 GangliosidosisPivotal-lookingActive, not recruiting
Azafaros B.V.Industry
NCT07082543 · 75 participants (planned) · Start Jun 30, 2025 · Primary completion Feb 6, 2028
Drug: AZ-3102; Placebo · For: Gangliosidoses, GM2; Gangliosidosis, GM1
Sites: Oakland, California; Minneapolis, Minnesota; Rochester, Minnesota · 27 sites in all
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)Pivotal-lookingRecruiting
Azafaros B.V.Industry
NCT07082725 · 72 participants (planned) · Start Jun 30, 2025 · Primary completion May 14, 2028
Drug: Nizubaglustat; Placebo · For: Niemann-Pick Type C Disease
Sites: Oakland, California; Minneapolis, Minnesota; Rochester, Minnesota · 34 sites in all
- A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C DiseaseActive, not recruiting
Azafaros B.V.Industry
NCT07399704 · 21 participants (planned) · Start Feb 4, 2026 · Primary completion Jun 30, 2027
Drug: AZ-3102 · For: GM2 Gangliosidosis; Niemann-Pick Type C Disease
Sites: Água Verde, Brazil; Porto Alegre, Brazil; Rio de Janeiro, Brazil
- Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)Not yet recruiting
Azafaros B.V.Industry
NCT07715084 · 20 participants (planned) · Start Jan 25, 2027 · Primary completion Jan 2028
Drug: AZ-3102 · For: Gaucher Disease Type 3
Sites: Jaipur, India; New Delhi, India; Lahore, Pakistan · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Levacetylleucine for the treatment of neurological manifestations of Niemann-Pick disease type C.
Strupp M, Churchill GC, Galione A, et al. · Expert Opin Pharmacother 2026
- Therapeutic Interventions in Niemann-Pick Disease Type C: A Systematic Review of Clinical Outcomes and Safety.
Nafees Z, Mohammed SSN, Bernhardt GV, et al. · Biomedicines 2026
- The RAINBOW study: a phase 2 trial evaluating the 3-month pharmacokinetic and pharmacodynamic data and 18-month clinical and safety outcomes of nizubaglustat in GM2 gangliosidoses or Niemann-Pick type C disease.
López de Frutos L, do Valle DA, Horovitz DDG, et al. · Mol Genet Metab 2026
- Therapeutic Effects of Nizubaglustat in a Mouse Model of GM2 Gangliosidosis.
Landskroner K, Singh K, Mitchell M, et al. · J Inherit Metab Dis 2026
- First-in-human single-dose study of nizubaglustat, a dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramidase: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending and multiple doses in healthy adults.
Paquet Luzy C, Doppler E, Polasek TM, et al. · Mol Genet Metab 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.